Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

New Onset Type-1 Diabetes

Interventions

BIOLOGICAL

Alpha-1 Antitrypsin

OTHER

Placebo

Trial Locations (4)

Soroka Medical Center, Beersheba

Rambam Medical Center, Haifa

Schneider Children's Medical Center, Pethach Tikva

Assaf Harofe Medical Center, Ẕerifin

All Listed Sponsors

lead

Kamada, Ltd.

INDUSTRY

NCT02005848 - Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes | Biotech Hunter | Biotech Hunter